Actually, although the efficacy of glibenclamide in reversing the vasodilation related to CGRP, PACAP, or prostacyclin and inhibiting cutaneous hypersensitivity in female mice injected with levcromakalim or glyceryl trinitrate was demonstrated in preclinical studies, it failed to prevent headache attacks induced by levcromakalim, PACAP38, or CGRP in humans, being only able to delay the onset of levcromakalim-induced headache [97,98,99]. The gene discussed is CALCA; the disease is Headache.